BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26530085)

  • 21. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
    García-Campelo R; Bernabé R; Cobo M; Corral J; Coves J; Dómine M; Nadal E; Rodriguez-Abreu D; Viñolas N; Massuti B
    Clin Transl Oncol; 2015 Dec; 17(12):1020-9. PubMed ID: 26691657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine.
    Murgu S; Colt H
    Clin Lung Cancer; 2013 Nov; 14(6):609-26. PubMed ID: 24188629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
    Chin LP; Soo RA; Soong R; Ou SH
    J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic concordance of non-small cell lung carcinoma subtypes between biopsy and cytology specimens obtained during the same procedure.
    Ebrahimi M; Auger M; Jung S; Fraser RS
    Cancer Cytopathol; 2016 Oct; 124(10):737-743. PubMed ID: 27172103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic and predictive analyses of cytological specimens of non-small cell lung cancer: strategies and challenges].
    Herth FJ; Bubendorf L; Gütz S; Morresi-Hauf A; Hummel M; Junker K; Lehmann U; Petersen I; Schnabel PA; Warth A
    Pneumologie; 2013 Apr; 67(4):198-204. PubMed ID: 23576199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
    Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
    Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
    Navani N; Butler R; Ibrahimo S; Verma A; Evans M; Doherty GJ; Ahmed S
    Lung Cancer; 2022 Oct; 172():142-153. PubMed ID: 36099709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment.
    Shackelford RE; Ansari JM; Wei EX; Alexander JS; Cotelingam J
    Pharmacogenomics; 2017 Aug; 18(12):1179-1192. PubMed ID: 28745554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.
    Popat S; Navani N; Kerr KM; Smit EF; Batchelor TJP; Van Schil P; Senan S; McDonald F
    Oncologist; 2021 Feb; 26(2):e306-e315. PubMed ID: 33145902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of cytological specimens for ALK fusion detection in patients with advanced NSCLC using the method of RT-PCR.
    Wang Y; Liu Y; Zhao C; Li X; Wu C; Hou L; Zhang S; Jiang T; Chen X; Su C; Gao G; Li W; Wu F; Li A; Ren S; Zhou C; Zhang J
    Lung Cancer; 2016 Apr; 94():28-34. PubMed ID: 26973203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. National Working Group Meeting on ALK diagnostics in lung cancer.
    Cooper W; Fox S; O'Toole S; Morey A; Frances G; Pavlakis N; O'Byrne K; Dettrick A; Leong T; Rathi V; Spagnolo D; Hemmings C; Singh M; Moffat D; Tsao MS; Wilner K; Buller R; Pitman Lowenthal S; Arifeen S; Binko J; Alam M
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl 2():11-7. PubMed ID: 24673736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
    Levy BP; Chioda MD; Herndon D; Longshore JW; Mohamed M; Ou SH; Reynolds C; Singh J; Wistuba II; Bunn PA; Hirsch FR
    Oncologist; 2015 Oct; 20(10):1175-81. PubMed ID: 26330460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010).
    Stinchcombe TE; Baggstrom MQ; Somaiah N; Simon GR; Govindan R
    J Thorac Oncol; 2011 Jan; 6(1):227-32. PubMed ID: 21178721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.